Oncogene activations were the first genetic alterations identified in neuroblastoma; initially MYCN amplification was identified in high-risk tumours4 and later ALK mutations were discovered in inherited neuroblastoma and some sporadic high-risk tumours5,6. This evidence concerns the gene ALK and neuroblastoma.